Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Completed 4Unknown 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Stomach Neoplasms 21Colorectal Neoplasms 8Colonic Neoplasms 6Carcinoma, Hepatocellular 6Rectal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Pancreatic Neoplasms 3Biliary Tract Neoplasms 3Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Gallbladder Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Cholangiocarcinoma 1

Interventions

Sorafenib 131lenvatinib 115Bevacizumab 88Radiosurgery 69atezolizumab 55sintilimab 54Nivolumab 51durvalumab 43Hepatectomy 43Fluorouracil 42apatinib 41Oxaliplatin 41camrelizumab 38Radiofrequency Ablation 38pembrolizumab 36Radiotherapy 36tislelizumab 35Leucovorin 31Magnetic Resonance Spectroscopy 30Immune Checkpoint Inhibitors 28Doxorubicin 28Folfox protocol 26tremelimumab 25regorafenib 25Cisplatin 20spartalizumab 19donafenib 19Gemcitabine 19Cyclophosphamide 19toripalimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Hepatocellular × Tegafur × Clear all
NCT03175679 2024-09-19

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Beijing YouAn Hospital

Phase 1 Completed
10 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03175705 2018-01-18

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Beijing YouAn Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02447679 2017-02-07

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Chang Gung Memorial Hospital

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Drug-Related Side Effects and Adverse Reactions

NCT00519688 2011-10-17

UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma

National Taiwan University Hospital

Phase 2 Completed
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00464919 2009-07-07

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

National Taiwan University Hospital

Phase 2 Completed
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00384800 2009-02-09

A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Far Eastern Memorial Hospital

Phase 2 Unknown
41 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡